Email this article Evidence-based medicine in nephrology
- Authors: Mukhin NA1
-
Affiliations:
- I. M. Sechenov Moscow Medical Academy
- Issue: Vol 82, No 6 (2010)
- Pages: 5-8
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30570
- ID: 30570
Cite item
Full Text
Abstract
The paper describes the specific features and perspective for introducing the principles of evidence-based medicine into Russian clinical nephrology
Keywords
About the authors
N A Mukhin
I. M. Sechenov Moscow Medical Academy
Email: moukhin-nephro@yandex.ru
д-р мед. наук, проф., акад. РАМН, зав. каф. терапии и профболезней, дир. клиники нефрологии, внутренних и профессиональных болезней им. Е. М. Тареева; ММА им. И. М. Сеченова; I. M. Sechenov Moscow Medical Academy
References
- Guyatt G. EBM Working Group. Evidence based medicine. A new approach to teaching the practice of medicine. J. A. M. A. 1992; 268: 2420-2425.
- Strippoli G. F., Craig J. C., Schena F. P. The number, quality and coverage of randomized controlled trials in nephrology. J. Am. Soc. Nephrol. 2004; 15 (2): 411-419.
- Coresh J., Selvin E., Stevens L. A. et al. Prevalence of chronic kidney disease in the United States. J. A. M. A. 2007; 298 (17): 2038-2047.
- Мухин Н. А., Моисеев В. С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестн. РАМН 2003; 11: 50-55.
- Смирнов А. В., Добронравов В. А., Каюков И. Г. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9 (3): 7-12.
- Ruggenenti P., Chiurchiu C., Abbate M. et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin. J. Am. Soc. Nephrol. 2006; 1 (4): 738-748.
- Ruggenenti P., Cravedi P., Sghirlanzoni M. C. et al. Effects of rituximab on morphofunctional abnormalities of membranous nephropathy. Clin. J. Am. Soc. Nephrol. 2008; 3 (6): 1652- 1659.
- Postma M. J., de Zeeuw D. The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus. Nephrol. Dial. Transplant. 2009; 24 (10): 2975- 2983.
- Hennig K., Woller P., Knoll P. Clinical experiences with 99m technetium-iron complex for renal scintigraphy - a comparison with mercury preparations. Fortschr. Röntgenstr. 1968; 109 (3): 366-374.
- Sharpstone P., Ogg C. S., Cameron J. S. Nephrotic syndrome due to primary renal disease in adultls. II. A controlled trial of prednisolone and azathioprine. Br. Med. J. 1969; 2 (5656): 535-539.
- Valkenburg H. A., Haverkorn M. J., Goslings W. R. et al. Streptococcal pharyngitis in the general population. II. The attack rate of rheumatic fever and acute glomerulonephritis in patients. J. Infect. Dis. 1971; 124 (4): 348-358.
- Ponticelli C., Zucchelli P., Imbasciati E. et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N. Engl. J. Med. 1984; 310: 946-950.
- Ponticelli C., Zucchelli P., Passerini P., Cesana B. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N. Engl. J. Med. 1992; 327: 599- 603.
- Ponticelli C., Zucchelli P., Passerini P. et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 1995; 48: 1600-1608.
- Maschio G., Alberti D., Janin G. et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334 (15): 939-945.
- The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349 (9069): 1857-1863.
- Brenner B. M., Cooper M. E., de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001; 345 (12): 861-869.
- Lewis E. J., Hunsicker L. G., Clarke W. R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001; 345: 851-860.
- Adogoa L. Y., Appel L., Bakris G. L. et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. J. A. M. A. 2001; 285: 2719-2728.
- Бикбов Б. Т., Томилина Н. А. Состояние заместительной терапии с хронической почечной недостаточностью в Российской Федерации в 1998-2008 гг. (отчет по данным Российского регистра заместительной почечной терапии). Нефрол. и диализ 2009; 11 (3): 141-149.
Supplementary files
